[Establishment of the methods to detect nucleophosmin gene and its mutation in acute myelogenous leukemia]

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Nucleophosmin (NPM) gene alterations are implicated in various cancers, including acute myelogenous leukemia (AML).
• Accurate detection methods for NPM gene expression and mutations are crucial for understanding AML pathogenesis and developing targeted therapies.

Purpose of the Study:

• To establish and evaluate Polymerase Chain Reaction (PCR)-based methods for detecting nucleophosmin (NPM) gene mRNA levels and specific mutations.
• To investigate the expression of NPM mRNA and the prevalence of NPM mutation A in acute myelogenous leukemia (AML) cell lines and patient specimens.

Main Methods:

• Reverse Transcription PCR (RT-PCR) was employed to quantify NPM mRNA levels in leukemia cell lines and 23 AML patient samples.
• PCR and sequencing were used to analyze the NPM gene's exon-12 in leukemia cell lines.
• A specific PCR assay was developed and validated to detect NPM mutation A, using a plasmid with known mutation A as a positive control.

Main Results:

• NPM mRNA expression was significantly higher in leukemia cell lines compared to normal cells.
• All 23 AML specimens exhibited varying levels of NPM mRNA overexpression.
• NPM mutation A was detected in 2 out of 23 AML specimens, while no NPM exon-12 mutations were found in THP1 and K562 cell lines, though a deletion was noted in K562's 3' UTR.

Conclusions:

• Established RT-PCR and PCR methods reliably detect NPM mRNA levels and NPM mutation A.
• NPM mRNA is consistently overexpressed in leukemia cells, and NPM mutation A is present in a subset of AML patients.
• These validated molecular tools are valuable for diagnosing and characterizing NPM alterations in AML.